Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

Genetic susceptibility to psoriasis: an emerging picture

(2012) Rhodri Smith et al.   Genome Medicine

Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis

(2009) James V Scanlon et al.   ANNALS OF PHARMACOTHERAPY

Progressive Multifocal Leukoencephalopathy, Efalizumab, and Immunosuppression

(2009) Benjamin D. Korman et al.   ARCHIVES OF DERMATOLOGY

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

(2009) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term safety of biologics in dermatology

(2009) Xinaida T. Lima et al.   Dermatologic Therapy

Psoriatic arthritis

(2009) Dafna D. Gladman   Dermatologic Therapy

Briakinumab

(2009) Xinaida Taligare Lima et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis

(2009) Zhenhua Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The pharmacokinetics of the fully human, interleukin-12/-23 monoclonal antibody (ABT-874) in normal healthy volunteers

(2009)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey

(2009) MA Radtke et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psoriatic arthritis: from pathogenesis to therapy

(2009) Oliver FitzGerald et al.   ARTHRITIS RESEARCH & THERAPY

New insights into the pathogenesis and genetics of psoriatic arthritis

(2009) Kristine E Nograles et al.   Nature clinical practice. Rheumatology

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease

(2008) Tim Bourne et al.   BIODRUGS

Tumor necrosis factor antagonists in the therapy of psoriasis

(2008) Rotraut Mössner et al.   CLINICS IN DERMATOLOGY

Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety

(2008) Michael P. Schön   CLINICS IN DERMATOLOGY

Alefacept in the treatment of psoriasis

(2008) Hideaki Sugiyama et al.   CLINICS IN DERMATOLOGY

Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis

(2008) Francesca Fantuzzi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Genetic Variants of the IL-23R Pathway: Association with Psoriatic Arthritis and Psoriasis Vulgaris, but No Specific Risk Factor for Arthritis

(2008) Ulrike Hüffmeier et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

(2008) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Polymorphisms in the IL-12β and IL-23R Genes Are Associated with Psoriasis of Early Onset in a UK Cohort

(2007) Rhodri Ll Smith et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY